Pathology & Genomics

病理

• 批准号: 10673949
• 负责人: David A Barbie
• 金额: $ 30.6万
• 依托单位: DANA-FARBER CANCER INST
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-08-01 至 2027-07-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10673949
• 关键词: Alleles; Anatomy; Antibodies; Area; Biochemical Pathway; Biochemical Process; Biological; Biological Assay; Biological Markers; Cancer Biology; Cancer Center; Caring; Cells; Certification; Clinical; Clinical Pathology; Clinical Treatment; Complement; Custom; Dana-Farber Cancer Institute; Databases; Detection of Minimal Residual Disease; Development; Diagnosis; Disease; Epidermal Growth Factor Receptor; Erlotinib; Etiology; Expression Profiling; Gefitinib; Gene Expression Profiling; Genetic; Genomics; Genotype; Goals; Histologic; Hybrids; Image; Immune; Immunofluorescence Immunologic; Immunohistochemistry; Immunophenotyping; In Situ; Individual; International; Intervention; Ions; Knowledge; Laboratories; Malignant Neoplasms; Malignant neoplasm of lung; Manuals; Massive Parallel Sequencing; Measures; Medicine; Microscopic; Molecular; Molecular Genetics; Monitor; Multiplexed Ion Beam Imaging; Mutation; Oncogenic; Pathologist; Pathology; Patient Monitoring; Patient Selection; Patients; Periodicity; Plasma; Procedures; Proteins; Protocols documentation; Quality Control; RNA analysis; ROS1 gene; Reproduction spores; Research; Research Personnel; Resources; Sampling; Scanning; Selection for Treatments; Seminal; Services; Slide; Specimen; Structure of parenchyma of lung; Supervision; System; Techniques; Technology; Tissue Banks; Tissue Microarray; Tissue Sample; Tissues; Transcript; Translational Research; Tumor Tissue; Validation; Vertebral column; Work; automated image analysis; automated segmentation; cancer cell; crizotinib; design; detection assay; immune cell infiltrate; immunoregulation; improved; inhibitor; innovation; molecular pathology; nano-string; next generation sequencing; novel; novel marker; protein biomarkers; protein expression; quality assurance; response; sample collection; sequencing platform; skills; standard of care; transcriptomics; treatment and outcome; tumor; tumor DNA; tumor microenvironment

Project Summary: The Integrated Pathology and Genomics Core provides state-of-the-art analytic services for lung cancer samples spanning the full spectrum from initial sample handling and processing, to microscopic analysis by certified anatomic pathologists, to immunophenotypic analysis, to molecular genetic and genomic analysis. This work constitutes the backbone of lung cancer management, and enables the diagnosis and proper treatment selection for patients with lung cancers of all types, and also enables research into cancer biology, etiology, and management. Our pathology core has supported work that has led to major advances in the understanding of lung cancer biology, and associated management thereof, including seminal discoveries of the importance of mutations in EGFR, ALK, ROS1, and MET in lung cancer, the diagnosis and management of which have become the international standard-of-care in this area of medicine. In the same manner, we intend to continue our work to advance the understanding and care of lung cancer, by supporting the new projects proposed herein, with a combination of standard-of-care and innovative new cutting-edge technologies. In this SPORE proposal, we will support each of the proposed projects with a combination of standard-of-care clinical pathology services - such as histologic characterization of tumors, immunohistochemical assessment of protein expression, and massively parallel sequencing of tumor DNA - and innovative new techniques. Among the innovative new techniques to be deployed for this project are customized allele-specific PCR assays for individual fusion transcripts to enable ultrasensitive monitoring of cell-free circulating ALK rearrangements in plasma samples, cyclic immunofluorescence and transcriptomics for simultaneous in situ spatial expression of multiple proteins and transcripts involved in various biochemical pathways, and multiplexed ion beam imaging to provide high-order assessment of immune cell infiltrates within and adjacent to cancers.

项目概要： 整合病理学和基因组学核心为肺癌样本提供最先进的分析服务 从最初的样品处理和加工到显微镜分析， 解剖病理学家，免疫表型分析，分子遗传学和基因组分析。这项工作 构成肺癌管理的支柱，并实现诊断和适当的治疗选择 对于所有类型的肺癌患者，还可以研究癌症生物学，病因学， 管理我们的病理学核心支持的工作，导致了重大进展的理解， 肺癌生物学及其相关管理，包括以下重要性的开创性发现： 肺癌中EGFR、ALK、ROS 1和MET的突变，其诊断和管理已成为 这一医学领域的国际护理标准。同样，我们打算继续我们的工作， 通过支持本文提出的新项目， 结合标准护理和创新的新尖端技术。 在此SPORE提案中，我们将支持每个拟议项目，并结合标准护理 临床病理学服务-如肿瘤的组织学特征， 蛋白质表达和肿瘤DNA的大规模平行测序-以及创新的新技术。之间 该项目将采用的创新性新技术是定制的等位基因特异性PCR检测， 单个融合转录物，能够超灵敏地监测无细胞循环ALK重排， 血浆样品，循环免疫荧光和转录组学，用于同时原位空间表达 多种蛋白质和转录物参与各种生化途径，以及多路离子束成像 以提供癌症内和癌旁免疫细胞浸润的高级评估。